DK3114139T3 - Anti eotaxin-2 antistoffer, der genkender supplerende ccr3-bindende chemokiner - Google Patents
Anti eotaxin-2 antistoffer, der genkender supplerende ccr3-bindende chemokiner Download PDFInfo
- Publication number
- DK3114139T3 DK3114139T3 DK15714963.4T DK15714963T DK3114139T3 DK 3114139 T3 DK3114139 T3 DK 3114139T3 DK 15714963 T DK15714963 T DK 15714963T DK 3114139 T3 DK3114139 T3 DK 3114139T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- recognize additional
- binding chemokines
- ccr3
- anti eotaxin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461947852P | 2014-03-04 | 2014-03-04 | |
| PCT/IL2015/050234 WO2015132790A2 (en) | 2014-03-04 | 2015-03-04 | Anti eotaxin-2 antibodies that recognize additional ccr3-binding chemokines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3114139T3 true DK3114139T3 (da) | 2022-09-12 |
Family
ID=52815066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15714963.4T DK3114139T3 (da) | 2014-03-04 | 2015-03-04 | Anti eotaxin-2 antistoffer, der genkender supplerende ccr3-bindende chemokiner |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10246508B2 (enExample) |
| EP (2) | EP3114139B1 (enExample) |
| JP (1) | JP6553075B2 (enExample) |
| CN (1) | CN106103479B (enExample) |
| BR (1) | BR112016020366B1 (enExample) |
| DK (1) | DK3114139T3 (enExample) |
| ES (1) | ES2926700T3 (enExample) |
| IL (1) | IL247219B (enExample) |
| PT (1) | PT3114139T (enExample) |
| RU (1) | RU2705255C2 (enExample) |
| WO (1) | WO2015132790A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017183028A1 (en) * | 2016-04-18 | 2017-10-26 | Chemomab Ltd. | Eotaxin-2 inhibitors in the treatment of fibromyalgia |
| WO2018106945A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| EP3554541B1 (en) | 2016-12-14 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| ES3052981T3 (en) | 2017-01-24 | 2026-01-16 | Kyowa Kirin Co Ltd | Therapeutic or prophylactic agent for treating radiation damage |
| GB201702500D0 (en) * | 2017-02-16 | 2017-04-05 | Univ Sheffield | Stable vamp reporter assay |
| IL251024A0 (en) * | 2017-03-08 | 2017-06-29 | Chemomab Ltd | Antibodies against eutaxin 2 for use in the treatment of liver diseases |
| EP3883635A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| WO2020185516A1 (en) | 2019-03-08 | 2020-09-17 | Auris Health, Inc. | Tilt mechanisms for medical systems and applications tilt mechanisms for medical systems and applications tilt mechanisms for medical systems and applications tilt mechanisms for medical systems and applications tilt mechanisms for medical systems and |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| US20230192836A1 (en) | 2020-04-20 | 2023-06-22 | Chemomab Ltd. | Ccl24 inhibitors in the treatment of covid-19 |
| CN115427445A (zh) | 2020-04-22 | 2022-12-02 | 彻莫马布有限公司 | 使用抗ccl24抗体的治疗方法 |
| EP4143227A2 (en) * | 2020-04-30 | 2023-03-08 | Sairopa B.V. | Anti-cd103 antibodies |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1303736B1 (it) * | 1998-11-11 | 2001-02-23 | San Raffaele Centro Fond | Peptidi derivati da rantes con attivita' anti-hiv. |
| CA2658496A1 (en) * | 2006-07-22 | 2008-01-31 | Oxagen Limited | 2-{5-fluoro-2-methyl-3-[2-(phenylsulfonyl)benzyl]-1h-indol-yl} acetic acid derivatives and esters thereof having crth2 antagonist activity |
| AU2010209273A1 (en) * | 2009-01-28 | 2011-09-01 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders |
| EP2470671B1 (en) * | 2009-08-28 | 2014-12-24 | Regeneron Pharmaceuticals, Inc. | Antikine antibodies that bind to multiple cc chemokines |
| GB201103837D0 (en) * | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
-
2015
- 2015-03-04 US US15/122,241 patent/US10246508B2/en active Active
- 2015-03-04 ES ES15714963T patent/ES2926700T3/es active Active
- 2015-03-04 PT PT157149634T patent/PT3114139T/pt unknown
- 2015-03-04 WO PCT/IL2015/050234 patent/WO2015132790A2/en not_active Ceased
- 2015-03-04 EP EP15714963.4A patent/EP3114139B1/en active Active
- 2015-03-04 BR BR112016020366-6A patent/BR112016020366B1/pt active IP Right Grant
- 2015-03-04 JP JP2016555467A patent/JP6553075B2/ja active Active
- 2015-03-04 RU RU2016136639A patent/RU2705255C2/ru active
- 2015-03-04 CN CN201580011755.4A patent/CN106103479B/zh active Active
- 2015-03-04 EP EP22165244.9A patent/EP4155317A1/en active Pending
- 2015-03-04 DK DK15714963.4T patent/DK3114139T3/da active
-
2016
- 2016-08-10 IL IL247219A patent/IL247219B/en unknown
-
2019
- 2019-02-07 US US16/270,231 patent/US10479830B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190153088A1 (en) | 2019-05-23 |
| IL247219A0 (en) | 2016-09-29 |
| EP4155317A1 (en) | 2023-03-29 |
| PT3114139T (pt) | 2022-09-13 |
| WO2015132790A3 (en) | 2015-11-05 |
| WO2015132790A2 (en) | 2015-09-11 |
| RU2705255C2 (ru) | 2019-11-06 |
| JP6553075B2 (ja) | 2019-08-07 |
| JP2017508461A (ja) | 2017-03-30 |
| ES2926700T3 (es) | 2022-10-27 |
| US20160368979A1 (en) | 2016-12-22 |
| CN106103479A (zh) | 2016-11-09 |
| US10479830B2 (en) | 2019-11-19 |
| EP3114139A2 (en) | 2017-01-11 |
| RU2016136639A (ru) | 2018-04-05 |
| US10246508B2 (en) | 2019-04-02 |
| EP3114139B1 (en) | 2022-06-15 |
| BR112016020366A2 (pt) | 2018-06-05 |
| RU2016136639A3 (enExample) | 2018-05-04 |
| IL247219B (en) | 2021-09-30 |
| CN106103479B (zh) | 2019-12-24 |
| BR112016020366B1 (pt) | 2024-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251963A0 (en) | Anti-pd-1 antibodies | |
| CL2015000230S1 (es) | Automóvil. | |
| DK3344654T3 (da) | Anti-lag-3-antistoffer | |
| CL2015002226S1 (es) | Automóvil. | |
| CL2015002104S1 (es) | Automovil. | |
| EP3319984C0 (en) | TAU LINKING ANTIBODIES | |
| CL2014001893S1 (es) | Vehiculo. | |
| PT3101032T (pt) | Onjugado de anticorpo anti-her2-fármaco | |
| LT3126395T (lt) | Daugiaspecifiniai antikūnai | |
| DK3350218T5 (da) | Polyomavirus-neutraliserende antistoffer | |
| CL2015002833S1 (es) | Automovil. | |
| DK3114139T3 (da) | Anti eotaxin-2 antistoffer, der genkender supplerende ccr3-bindende chemokiner | |
| IL291164A (en) | Anti-nme antibody | |
| CL2014002997S1 (es) | Neumatico. | |
| DK3157559T3 (da) | Anti-axl-antistoffer | |
| HUE060878T2 (hu) | Anti-transztiretin antitestek | |
| BR112017012364A2 (pt) | pré-tratamento rápido. | |
| DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
| EP3319983C0 (en) | TAU LINKING ANTIBODIES | |
| CL2015002137S1 (es) | Automovil. | |
| FR3023988B3 (fr) | . | |
| PL3092003T3 (pl) | Nowe przeciwciało przeciw netrynie-1 | |
| CL2014001836S1 (es) | Neumatico. | |
| HUE054148T2 (hu) | Anti-ORAI1 antitest | |
| LT3126391T (lt) | Hpa-1a antikūnai |